These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10610580)

  • 1. Docetaxel (Taxotere): a new option for the treatment of hormone-refractory prostate cancer. Proceedings of a symposium. Chicago, Illinois, USA. April 23, 1999.
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):1-68. PubMed ID: 10610580
    [No Abstract]   [Full Text] [Related]  

  • 2. Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.
    Vogelzang NJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):1-2. PubMed ID: 10604260
    [No Abstract]   [Full Text] [Related]  

  • 3. Docetaxel (Taxotere): preclinical and general clinical information.
    Earhart RH
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):8-13. PubMed ID: 10604262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
    Friedland D; Cohen J; Miller R; Voloshin M; Gluckman R; Lembersky B; Zidar B; Keating M; Reilly N; Dimitt B
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):19-23. PubMed ID: 10604264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxanes in hormone-refractory prostate cancer.
    Kang MH; Figg WD; Dahut W
    Cancer Pract; 1999; 7(5):270-2. PubMed ID: 10687598
    [No Abstract]   [Full Text] [Related]  

  • 7. Controversies in chemotherapy of prostate cancer.
    Heicappell R
    Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
    [No Abstract]   [Full Text] [Related]  

  • 8. Hormone-refractory prostate cancer: an evolving standard of care.
    Small EJ; Reese DM; Vogelzang NJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):61-7. PubMed ID: 10604272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy combination shows efficacy in hormone-refractory prostate cancer.
    Oncology (Williston Park); 1999 Jul; 13(7):1014. PubMed ID: 10442347
    [No Abstract]   [Full Text] [Related]  

  • 11. Docetaxel (taxotere) in the treatment of prostate cancer.
    Beer TM; El-Geneidi M; Eilers KM
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):261-8. PubMed ID: 12820771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of taxanes in prostate cancer.
    Stein CA
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):3-7. PubMed ID: 10604261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel (Taxotere) in the treatment of cancer.
    Burris HA
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):1-2. PubMed ID: 10810931
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chemotherapy of prostate cancer: potential role of docetaxel].
    Bracarda S
    Tumori; 2001; 87(6):A12-4. PubMed ID: 11995697
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel.
    Sallah S; Gagnon GA
    Cancer Invest; 2000; 18(3):191-6. PubMed ID: 10754987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
    Petrylak DP; Macarthur R; O'Connor J; Shelton G; Weitzman A; Judge T; England-Owen C; Zuech N; Pfaff C; Newhouse J; Bagiella E; Hetjan D; Sawczuk I; Benson M; Olsson C
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):28-33. PubMed ID: 10604266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
    Oh WK; Kantoff PW
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel in prostate cancer.
    Small EJ
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxing the taxanes: overused or undersold?
    Miller M
    J Natl Cancer Inst; 1999 Dec; 91(24):2077-8. PubMed ID: 10601377
    [No Abstract]   [Full Text] [Related]  

  • 20. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
    Weitzman AL; Shelton G; Zuech N; Owen CE; Judge T; Benson M; Sawczuk I; Katz A; Olsson CA; Bagiella E; Pfaff C; Newhouse JH; Petrylak DP
    J Urol; 2000 Mar; 163(3):834-7. PubMed ID: 10687988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.